The Morrison & Foerster BioMeter for the first quarter of 2013 shows a flat quarter for BioMeter value and a decline in dealmaking activity. A small number of large deals dominate an otherwise quiet quarter.

In the first quarter of 2013, the average BioMeter value for all transactions was approximately $60 million, a significant increase compared to the same quarter in 2012. Much of this value is attributable to two transactions, however, the BMS/Reckitt transaction for multiple OTC products in Latin America, and the AstraZeneca/Moderna transaction for mRNA technology. Excluding these two transactions, the BioMeter value for the first quarter was $16.3 million, a slight decline from the same quarter in 2012.